These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 19712857

  • 21. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease.
    Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A.
    Respir Med; 2007 Oct; 101(10):2139-44. PubMed ID: 17629470
    [Abstract] [Full Text] [Related]

  • 22. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis.
    Hedlund J.
    Scand J Infect Dis Suppl; 1995 Oct; 97():1-60. PubMed ID: 8584866
    [Abstract] [Full Text] [Related]

  • 23. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 24. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations.
    Antonescu-Turcu AL, Tomic R.
    Curr Opin Pulm Med; 2009 Mar; 15(2):120-5. PubMed ID: 19532026
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Bacteriological differences between COPD exacerbation and community-acquired pneumonia.
    Li XJ, Li Q, Si LY, Yuan QY.
    Respir Care; 2011 Nov; 56(11):1818-24. PubMed ID: 21605476
    [Abstract] [Full Text] [Related]

  • 28. Relation of sputum colour to bacterial load in acute exacerbations of COPD.
    Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, Telgen MC, van der Palen J, Hendrix MG, van der Valk PD.
    Respir Med; 2009 Apr; 103(4):601-6. PubMed ID: 19027281
    [Abstract] [Full Text] [Related]

  • 29. Limited usefulness of initial blood cultures in community acquired pneumonia.
    Corbo J, Friedman B, Bijur P, Gallagher EJ.
    Emerg Med J; 2004 Jul; 21(4):446-8. PubMed ID: 15208227
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. C-reactive protein to distinguish pneumonia from acute decompensated heart failure.
    Joffe E, Justo D, Mashav N, Swartzon M, Gur H, Berliner S, Paran Y.
    Clin Biochem; 2009 Nov; 42(16-17):1628-34. PubMed ID: 19703436
    [Abstract] [Full Text] [Related]

  • 32. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
    Drescher GS, Carnathan BJ, Imus S, Colice GL.
    Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
    [Abstract] [Full Text] [Related]

  • 33. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease.
    Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadağ F.
    Scand J Clin Lab Invest; 2009 Dec; 69(2):219-24. PubMed ID: 18946779
    [Abstract] [Full Text] [Related]

  • 34. Highly elevated C-reactive protein levels in obese patients with COPD: a fat chance?
    Breyer MK, Spruit MA, Celis AP, Rutten EP, Janssen PP, Wouters EF, CIRO Network.
    Clin Nutr; 2009 Dec; 28(6):642-7. PubMed ID: 19540024
    [Abstract] [Full Text] [Related]

  • 35. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
    Schouten JA, Hulscher ME, Trap-Liefers J, Akkermans RP, Kullberg BJ, Grol RP, van der Meer JW.
    Clin Infect Dis; 2007 Apr 01; 44(7):931-41. PubMed ID: 17342644
    [Abstract] [Full Text] [Related]

  • 36. Value of rapid aetiological diagnosis in optimization of antimicrobial treatment in bacterial community acquired pneumonia.
    Mareković I, Plecko V, Boras Z, Pavlović L, Budimir A, Bosnjak Z, Puretić H, Zele-Starcević L, Kalenić S.
    Coll Antropol; 2012 Jun 01; 36(2):401-8. PubMed ID: 22856222
    [Abstract] [Full Text] [Related]

  • 37. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features.
    Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falcó M, Muñoz J.
    Am J Emerg Med; 2007 Jun 01; 25(5):515-22. PubMed ID: 17543654
    [Abstract] [Full Text] [Related]

  • 38. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M, Biddle AK, Stearns SC.
    Clin Ther; 2008 Jun 01; 30 Spec No():1003-16. PubMed ID: 18640475
    [Abstract] [Full Text] [Related]

  • 39. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients.
    Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, Bello S, Martin-Loeches I, Menéndez R, Torres A.
    Eur Respir J; 2012 Apr 01; 39(4):855-61. PubMed ID: 21920895
    [Abstract] [Full Text] [Related]

  • 40. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD.
    J Antimicrob Chemother; 2008 May 01; 61(5):1162-8. PubMed ID: 18310136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.